Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 placeSee list

Mizuho maintains Outperform rating on CVS Health shares

EditorTanya Mishra
Published 10/02/2024, 09:02 AM
CVS
-

Mizuho has reaffirmed its positive stance on CVS Health (NYSE: NYSE:CVS), maintaining both the Outperform rating and the $66.00 price target for the company's shares.

The firm's commentary focused on recent speculations that CVS Health is considering a potential split of its retail pharmacy and insurance units. Mizuho expressed skepticism about the likelihood of such a separation occurring.

The firm elaborated that, in the event of a split, the pharmacy benefit manager (PBM) would likely remain with CVS's retail division, while Oak Street Health could be spun off with Aetna. Mizuho argued that the PBM is too integrated with CVS's retail operations, providing significant revenue synergies that would be challenging to untangle. The analyst highlighted the PBM's contribution to the retail segment's market share growth over the past two decades.

Additionally, the firm pointed out that the health insurance segment's competitiveness in Medicare Advantage Prescription Drug (MAPD) plans would be compromised without the PBM, further complicating any potential separation.

CVS Health laid off approximately 2,900 employees and the introduction of new Medicare Advantage plans with a $0 monthly premium on prescription drugs.

The company is also said to be considering a strategic split of its retail and insurance operations. This decision follows private discussions with Glenview Capital Management, a stakeholder in CVS Health, about the need to improve the company's operational performance. Evercore ISI and Leerink Partners have offered their analysis on the potential breakup, highlighting both the opportunities and challenges that could arise from such a move.

InvestingPro Insights

Adding to Mizuho's analysis of CVS Health's potential split and its $66.00 price target, InvestingPro data provides additional context for investors. CVS's current market cap stands at $77.42 billion, with a P/E ratio of 10.87, suggesting the stock may be undervalued relative to its earnings. This aligns with an InvestingPro Tip indicating that CVS is "Trading at a low revenue valuation multiple."

The company's revenue growth of 7.03% over the last twelve months demonstrates its continued expansion in the healthcare sector. CVS also boasts a healthy dividend yield of 4.32%, which is particularly noteworthy given another InvestingPro Tip: "Has maintained dividend payments for 54 consecutive years." This long-term commitment to shareholder returns could be a factor in Mizuho's Outperform rating.

Interestingly, while Mizuho's price target is $66.00, the InvestingPro Fair Value estimate stands higher at $75.37, suggesting potential upside that investors might consider. For those seeking a deeper understanding of CVS's financial health and market position, InvestingPro offers 8 additional tips, which could provide valuable insights into the company's prospects amidst discussions of potential structural changes.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.